GlobeNewswire PharmaOriginal article
Boehringer Ingelheim launches SCOVELLA® in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis
RegulatoryapprovedSCOVELLA®Positive
AI Analysis
Summary
Boehringer Ingelheim launched SCOVELLA® in Great Britain, the first approved therapy for insulin dysregulation in horses, a major cause of laminitis.
Outcome Details
First approved therapy for insulin dysregulation in horses in Great Britain
Importance:6/10
Sentiment:
0.80
regulatory approvalveterinary medicinelaminitisUK marketfirst-in-class
Read the original article
Published by GlobeNewswire Pharma on September 1, 2026 8:00 AM